This approach uses bispecific antibodies to simultaneously bind CD3 on T cells and specific antigens on target cells, such as B cell maturation antigen (BCMA) or CD19 on B cells and plasma cells, thereby activating T cells to mediate the targeted destruction of pathogenic cells in autoimmune diseases. This evidence concerns the gene TNFRSF17 and autoimmune disease.